Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy

Diabetologia

Volumn 45, Issue 11, 2002, Pages 1562-1571

  Atchley, D ^a,b,c,d   Lopes Virella, M ^a,b,c,d   Zheng, D ^a,b,c,d   Kenny, D ^a,b,c,d   Virella, G ^a,b,c,d  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Autoimmunity; Immune complexes; Oxidized LDL; Oxidized LDL antibodies; Type I diabetes

Indexed keywords

HEMOGLOBIN A1C; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ANTIBODY AFFINITY; ANTIBODY ISOLATION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPLEX FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; ALBUMINURIA; BLOOD; IMMUNOLOGY; REFERENCE VALUE;

ADULT; ALBUMINURIA; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; CHOLESTEROL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; REFERENCE VALUES; TRIGLYCERIDES;

EID: 0036435829     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-002-0962-y     Document Type: Article

References (71)

1. Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ (1996) Coronary artery disease in IDDM, gender differences in risk factor but not risk. Arterioscler Thromb Vasc Biol 16: 720-726
2. Maser RE, Wolfson SK Jr, Ellis D et al. (1991) Cardiovascular disease and arterial calcification in insulin-dependent diabetes mellitus: Interactions and risk factor profiles. Pittsburgh Epidemiology of Diabetes Complications Study (V). Arterioscler Thromb 11: 958-965
3. Orchard TJ, Dorman JS, Maser RE et al. (1990) Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study (II). Diabetes 39: 1116-1124
4. De Cosmo S, Bacci S, Piras GP et al. (1997) High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria. Diabetologia 40: 1191-1196
5. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T (1987) Coronary heart disease in young Type I (insulin dependent) diabetic patients with and without diabetic nephropathy: Incidence and risk factors. Diabetologia 30: 144-148
6. Groop PH, Elliott T, Ekstrand A et al. (1996) Multiple lipoprotein abnormalities in type I diabetic patients with renal disease. Diabetes 45: 974-979
7. Hirano T (1999) Lipoprotein abnormalities in diabetic nephropathy. Kidney Int 71 [Suppl]: S22-S24
8. Salahudeen AK, Kanji V, Reckelhoff JF, Schmidt AM (1997) Pathogenesis of diabetic nephropathy: A radical approach. Nephrol Dial Transplant 12: 664-668
9. Diamond JR (1991) Analogous pathobiological mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int 39 [Suppl]: S29-S34
10. Witztum JL (1994) The oxidation hypothesis of atherosclerosis. Lancet 344: 793-795
11. Lopes-Virella MF, Virella G (1998) The immunology of atherosclerosis. In: Marshall SM, Home PD, Rizza RA (eds) Diabetes Annual 11, Elsevier, Amsterdam, pp 81-85
12. Witztum JL (1994) The role of oxidized LDL in the atherogenic process. J Atheroscler Thromb 1: 71-75
13. French JW, Yamanaka BS, Oswald R (1967) Dietary induced glomerulosclerosis in the guinea pig. Arch Pathol Lab Med 83: 204-210
14. Lopes-Virella MF, Virella G, Orchard TJ et al. (1999) Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus Clin Immunol 90: 165-172
15. Steinbrecher UP, Eisher M, Witztum JL, Curtiss LK (1984) Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: Generation of antibodies specific for derivatized lysine. J Lipid Res 25: 1109-1116
16. Lopes-Virella MF, Griffith RL, Shunk KA, Virella GT (1991) Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler Thromb 11: 1356-1367
17. Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MF (1993) Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res 23: 95-101
18. Wick G, Xu Q (1999) Atherosclerosis-an autoimmune disease. Exp Gerontol 34: 559-566
19. Klimov AN, Denisenko AD, Vinogradov AG et al. (1988) Accumulation of cholesteryl esters in macrophages incubated with human lipoprotein-antibody autoimmune complex. Atherosclerosis 74: 41-46
20. Mironova M, Virella G, Virella-Lowell I, Lopes-Virella MF (1997) Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls Clin Immunol Immunopathol 85: 73-82
21. Tertov VV, Orekhov AN, Kacharava AG, Sobenin IA, Perova NV, Smirnov VN (1990) Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis. Exp Mol Pathol 52: 300-308
22. Tertov VV, Orekhov AN, Sayadyan KS et al. (1990) Correlation between cholesterol content and circulating immune complexes and atherogenic properties of CHD patients' serum manifested in cell culture. Atherosclerosis 81: 183-189
23. Griffith RL, Virella GT, Stevenson HC, Lopes-Virella MF (1988) Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med 168: 1041-1059
24. Orchard TJ, Virella G, Forrest KY, Evans RW, Becker DJ, Lopes-Virella MF (1999) Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: A nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 48: 1454-1458
25. ADA (2000) Standards of medical care for patients with diabetes mellitus. Diabetes Care 23: S32-S64.
26. Koskinen S, Enockson C, Lopes-Virella MF, Virella G (1998) Preparation of a human standard for determination of the levels of antibodies to oxidatively modified low-density lipoproteins. Clin Diagn Lab Immunol 5: 817-822
27. Mironova M, Virella G, Lopes-Virella MF (1996) Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol 16: 222-229
28. Virella G, Koskinen S, Krings G, Onorato JM, Thorpe SR, Lopes-Virella M (2000) Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies Clin Immunol 95: 135-144
29. Chenais F, Virella G, Patrick CC, Fudenberg HH (1977) Isolation of soluble immune complexes by affinity chromatography using staphylococcal protein A-sepharose as substrate. J Immunol Methods 18: 188-192
30. Hara A, Radin NS (1978) Lipid extraction of tissues with a low-toxicity solvent Anal Biochem 90: 420-426
31. Lopes-Virella MF, Sherer GK, Lees AM et al. (1982) Surface binding, internalization and degradation by cultured human fibroblasts of low density lipoproteins isolated from Type I (insulin-dependent) diabetic patients: Changes with metabolic control. Diabetologia 22: 430-436
32. Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg M (1985) Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods 77: 305-309
33. Gin H, Rigalleau V, Aparicio M (2000) Lipids, protein intake, and diabetic nephropathy. Diabetes Metab 26: 45-53
34. Al-Shebeb T, Frohlich J, Magil AB (1988) Glomerular disease in hypercholesterolemic guinea pigs: A pathogenetic study. Kidney Int 33: 498-507
35. Moorhead JF (1991) Lipids and progressive kidney disease. Kidney Int 39: S35-S40
36. Bergmark C, Wu R, de Faire U, Lefvert AK, Swedenborg J (1995) Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 15: 441-445
37. Boullier A, Walters-Laporte E, Hamon M et al. (2000) Absence of relationship between plasma Lp(a), Lp-AI, anti-oxidized LDL autoantibodies, LDL immune complexes concentrations and restenosis after percutaneous transluminal coronary angioplasty. Clin Chim Acta 299: 129-140
38. Dotevall A, Hulthe J, Rosengren A, Wiklund O, Wilhelmsen L (2001) Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women Clin Sci (Colch) 101: 523-531
39. Erkkilä AT, Närvänen O, Lehto S, Uusitupa MIJ, Ylä-Herttuala S (2000) Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 20: 204-209
40. Inoue T, Uchida T, Kamishirado H, Takayanagi K, Morooka S (2001) Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease J Am Coll Cardiol 37: 1871-1876
41. Inoue T, Inoue K, Maeda H, Takayanagi K, Morooka S (2001) Immunological response to oxidized LDL occurs in association with oxidative DNA damage independently of serum LDL concentrations in dyslipidemic patients. Clin Chim Acta. 305: 115-121
42. Jansen H, Ghanem H, Kuypers J, Birkenhager JC (1995) Autoantibodies against malondialdehyde-modified LDL are elevated in subjects with an LDL subclass patternB. Atherosclerosis 115: 255-262
43. Lehtimaki T, Lehtinen S, Solakivi T et al. (1999) Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 19: 23-27
44. Maggi E, Chiesa R, Melissano G et al. (1994) LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 14: 1892-1899
45. Puurunen M, Mänttäri M, Manninen V et al. (1994) Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 154: 2605-2609
46. Salonen JT, Yla-Herttuala S, Yamamoto R et al. (1992) Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339: 883-887
47. Boullier A, Hamon M, Walters-Laporte E et al. (1995) Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease. Clin Chim Acta 238: 1-10
48. Hulthe J, Bokemark L, Fagerberg B (2001) Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 21: 101-107
49. Leinonen JS, Rantalaiho V, Laippala P et al. (1998) The level of autoantibodies against oxidized LDL is not associated with the presence of coronary heart disease or diabetic kidney disease in patients with non-insulin-dependent diabetes mellitus. Free Radic Res 29: 137-141
50. Uusitupa MI, Niskanen L, Luoma J et al. (1996) Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 16: 1236-1242
51. van de Vijver LP, Steyger R, van Poppel G et al. (1996) Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis 122: 245-253
52. Wu R, de Faire U, Lemne C, Witztum JL, Frostegard J (1999) Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 33: 53-59
53. Festa A, Kopp HP, Schernthaner G, Menzel EJ (1998) Autoantibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications. Diabetologia 41: 350-356
54. Palinski W, Miller E, Witztum JL (1995) Immunization of low density lipoprotein (LDL) receptor deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 92: 821-825
55. George J, Afek A, Gilburd B et al. (1998) Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138: 147-152
56. Freigang S, Horkko S, Miller E, Witztum JL, Palinski W (1998) Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 18: 1972-1982
57. Shaw PX, Horkko S, Tsimikas S et al. (2001) Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 21: 1333-1339
58. Virella G (2001) Immunoglobulin structure. In: Virella G (ed) Medical Immunology, 5th Edn. Marcel Dekker, New York/Basel, pp 77-91
59. Lopes-Virella MF, Binzafar N, Rackley S, Takei A, La Via M, Virella G (1997) The uptake of LDL-IC by human macrophages: Predominant involvement of the Fc gamma RI receptor. Atherosclerosis 135: 161-170
60. Huang Y, Jaffa A, Koskinen S, Takei A, Lopes-Virella MF (1999) Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler Thromb Vasc Biol 19: 1600-1607
61. Kiener PA, Rankin BM, Davis PM, Yocum SA, Warr GA, Grove RI (1995) Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler Thromb Vasc Biol 15: 990-999
62. Virella G, Munoz JF, Galbraith GM, Gissinger C, Chassereau C, Lopes-Virella MF (1995) Activation of human monocyte-derived macrophages by immune complexes containing low-density lipoprotein. Clin Immunol Immunopathol 75: 179-189
63. Orekhov AN, Kalenich OS, Tertov VV, Novikov ID (1991) Lipoprotein immune complexes as markers of atherosclerosis. Int J Tissue React 13: 233-236
64. Korpinen E, Groop PH, Akerblom HK, Vaarala O (1997) Immune response to glycated and oxidized LDL in IDDM patients with and without renal disease. Diabetes Care 20: 1168-1171
65. Winfield JB, Faiferman I, Koffler D (1977) Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest 59: 90-96
66. Theofilopoulos AN, Dixon FJ (1979) The biology and detection of immune complexes. Adv Immunol 28: 89-220
67. Virella G (2001) Biosynthesis, metabolism, and biological properties of immunoglobulins. In: Virella G (ed) Medical Immunology, 5th Edn. Marcel Dekker, New York/Basel, pp 93-204
68. Moorhead JF, Brunton C, Varghese Z (1997) Glomerular atherosclerosis. Miner Electrolyte Metab 23: 287-290
69. Wheeler DC, Chana RS, Topley N, Petersen MM, Davies M, Williams JD (1994) Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Int 45: 1628-1636
70. Uciechowski P, Schwarz M, Gessner JE, Schmidt RE, Resch K, Radeke HH (1998) IFN-gamma induces the high-affinity Fc receptor I for IgG (CD64) on human glomerular mesangial cells. Eur J Immunol 28: 2928-2935
71. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK (1995) T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 92: 3893-3897